EcoDrugPlus

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSCHYG00000025885
Gene Symbol: SCNN1A
1 Cross references
153 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSCHYG00000023841
Gene Symbol: SCNN1B
1 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSCHYG00000023767
Gene Symbol: SCNN1G
1 Cross references
155 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSCHYG00000026209
Gene Symbol: SCN1A
1 Cross references
140 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSCHYG00000026482
Gene Symbol: SCN10A
1 Cross references
302 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSCHYG00000026462
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSCHYG00000009387
Gene Symbol: SCN2A
1 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSCHYG00000009659
Gene Symbol: SCN3A
1 Cross references
133 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCHYG00000012837
Gene Symbol: SCN4A
1 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSCHYG00000013862
Gene Symbol: SCN5A
1 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSCHYG00000026057
Gene Symbol: SCN7A
1 Cross references
85 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCHYG00000001445
Gene Symbol: SCN8A
1 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).